Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-0.56% $1.780
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 87.29 mill |
EPS: | -0.560 |
P/E: | -3.18 |
Earnings Date: | May 05, 2024 |
SharesOutstanding: | 49.04 mill |
Avg Daily Volume: | 0.216 mill |
RATING 2024-03-28 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | ||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -3.18 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.54x |
Company: PE -3.18 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.234 (-86.84%) $-1.546 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 1.612 - 1.948 ( +/- 9.44%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-28 | Arcara Jeffrey | Buy | 400 000 | Stock Option (Right to Buy) |
2024-02-02 | Arcara Jeffrey | Buy | 0 | |
2023-12-06 | Miller Richard A Md | Buy | 500 000 | Stock Option (Right to Buy) |
2023-12-06 | Lea Leiv | Buy | 200 000 | Stock Option (Right to Buy) |
2023-12-06 | Jones William Benton | Buy | 200 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
100.00 |
Last 97 transactions |
Buy: 8 310 910 | Sell: 8 757 350 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.780 (-0.56% ) |
Volume | 0.273 mill |
Avg. Vol. | 0.216 mill |
% of Avg. Vol | 126.14 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.